Veracyte VCYT Business Segments — Direct expense

Similar metrics at other companies

GXOReportable Segment — Direct operating expense

$2.81B+9.8%

RXOReportable Segment — Direct operating expense (exclusive of depreciation and amortization)

$50M+4.2%

MEDPReportable Segment — Total direct costs

$510.28M+34.2%

NSAReportable Segment — Operating Costs and Expenses

$52.03M-5.6%

UEReportable Segment — Total Costs & Expenses

$48.46M+11.7%

GRALReportable Segment — Total Costs & Expenses

$176.55M-4.8%

Questions, answered.

What is Veracyte's business segments — direct expense?

Veracyte (VCYT) reported business segments — direct expense of $4.2M in Q1 2026.

How has Veracyte's business segments — direct expense changed year-over-year?

Veracyte's business segments — direct expense increased by 1.4% year-over-year, from $4.14M to $4.2M.

What is the long-term trend for Veracyte's business segments — direct expense?

Over 3 years (2022 to 2025), Veracyte's business segments — direct expense has grown at a 39.3% compound annual growth rate (CAGR), from $6.14M to $16.6M.

What does business segments — direct expense mean?

Represents the specific, traceable operating costs directly incurred by the reportable segment to support its business activities. This metric helps isolate the segment's operational footprint from shared corporate overhead.